ACTR-II Antibody (149/1): sc-57022

ACTR-II Antibody (149/1) is a mouse monoclonal IgG1 antibody that detects ACTR-II in mouse, rat, and human samples through applications such as western blotting (WB) and immunoprecipitation (IP). ACTR-II, also known as activin receptor type IIB, plays a crucial role in the transforming growth factor beta (TGF-β) superfamily signaling pathway, which is essential for various cellular processes including cell differentiation, proliferation, and apoptosis. Anti-ACTR-II antibody (149/1) recognizes this receptor primarily on the cell membrane, where ACTR-II forms a heteromeric complex with type I receptors, facilitating the binding of activin ligands. Proper localization of ACTR-II is vital as ACTR-II ensures effective signal transduction, allowing cells to respond appropriately to extracellular cues. Dysregulation of ACTR-II has been implicated in several pathological conditions, including cancer and fibrotic diseases, highlighting ACTR-II′s importance in maintaining cellular homeostasis. ACTR-II monoclonal antibody (149/1) serves as an invaluable tool for researchers studying the intricate mechanisms of TGF-β signaling and its implications in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

ACTR-II Antibody (149/1) References:

1. The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly.  |  Greenwald, J., et al. 2003. Mol Cell. 11: 605-17. PMID: 12667445
2. The interaction of BMP-7 and ActRII implicates a new mode of receptor assembly.  |  Sebald, W. and Mueller, TD. 2003. Trends Biochem Sci. 28: 518-21. PMID: 14559178
3. Loss of heterozygosity and mutational analyses of the ACTRII gene locus in human colorectal tumors.  |  Olaru, A., et al. 2003. Lab Invest. 83: 1867-71. PMID: 14691305
4. Involvement of the bone morphogenetic protein/receptor system during follicle development in the bovine ovary: Hormonal regulation of the expression of bone morphogenetic protein 7 (BMP-7) and its receptors (ActRII and ALK-2).  |  Shimizu, T., et al. 2006. Mol Cell Endocrinol. 249: 78-83. PMID: 16513253
5. BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II.  |  Kim, JH., et al. 2012. Angiogenesis. 15: 497-509. PMID: 22622516
6. ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments.  |  Hatakeyama, S., et al. 2016. Skelet Muscle. 6: 26. PMID: 27462398
7. Detection of the Human Anti-ActRII Antibody Bimagrumab in Serum by Means of Affinity Purification, Tryptic Digestion, and LC-HRMS.  |  Walpurgis, K., et al. 2018. Proteomics Clin Appl. 12: e1700120. PMID: 29226558
8. Combined detection of the ActRII-Fc fusion proteins Sotatercept (ActRIIA-Fc) and Luspatercept (modified ActRIIB-Fc) in serum by means of immunoaffinity purification, tryptic digestion, and LC-MS/MS.  |  Walpurgis, K., et al. 2018. Drug Test Anal. 10: 1714-1721. PMID: 30285318
9. ACTRII signalling implicated in HF.  |  Lim, GB. 2019. Nat Rev Cardiol. 16: 258. PMID: 30874631
10. ActRII takes centre stage in heart failure.  |  Kingwell, K. 2019. Nat Rev Drug Discov.. PMID: 31048800

The preferred ACTR-IIB antibody is ACTR-IIB Antibody (G-7): sc-376593.